Disrupted bone morphogenetic protein type 2 receptor(BMPR2)signaling in endothelial cells drives pulmonary arterial hypertension(PAH).However,targeted recovery of this signaling pathway by lipid nanoparticles(LNPs)has...Disrupted bone morphogenetic protein type 2 receptor(BMPR2)signaling in endothelial cells drives pulmonary arterial hypertension(PAH).However,targeted recovery of this signaling pathway by lipid nanoparticles(LNPs)has not been explored as a therapy.Here,we employed Design of Experiments to optimize the delivery efficiency of LNPs targeting pulmonary endothelial cells developed by our laboratory,resulting in a remarkable 35-fold increase in a simplified three-component formulation without helper lipids.Administration of BMPR2 mRNA LNPs effectively reversed established PAH in two experimental rat models(monocrotaline or SU5416-hypoxia)by reversing pulmonary vascular remodeling.Specifically,BMPR2 mRNA LNPs replenished the expression of BMPR2 protein and subsequently activated downstream pathways,as confirmed by elevated levels of p-SMAD1/5/9 and ID1 proteins.The relief of pulmonary arterial occlusion was demonstrated by thinned pulmonary arterial media and decreased proportion of full muscularized vessels.Alleviation of right ventricular hypertrophy was indicated by declined Fulton index,the cross-sectional area of right ventricular cardiomyocytes as well as collagen deposition.Effective recovery of right ventricular function was evidenced by increased pulmonary artery flow acceleration time/pulmonary artery flow ejection time ratio.These findings underscore the potential of restoring BMPR2 signaling through pulmonary endothelial cell-specific LNPs for treating PAH.展开更多
基金sponsored by Science and Technology Commission of Shanghai Municipality(YDZX20223100001002,China)the Natural Science Foundation of Shanghai(25ZR1401251)the ShanghaiTech University Startup Grant.
文摘Disrupted bone morphogenetic protein type 2 receptor(BMPR2)signaling in endothelial cells drives pulmonary arterial hypertension(PAH).However,targeted recovery of this signaling pathway by lipid nanoparticles(LNPs)has not been explored as a therapy.Here,we employed Design of Experiments to optimize the delivery efficiency of LNPs targeting pulmonary endothelial cells developed by our laboratory,resulting in a remarkable 35-fold increase in a simplified three-component formulation without helper lipids.Administration of BMPR2 mRNA LNPs effectively reversed established PAH in two experimental rat models(monocrotaline or SU5416-hypoxia)by reversing pulmonary vascular remodeling.Specifically,BMPR2 mRNA LNPs replenished the expression of BMPR2 protein and subsequently activated downstream pathways,as confirmed by elevated levels of p-SMAD1/5/9 and ID1 proteins.The relief of pulmonary arterial occlusion was demonstrated by thinned pulmonary arterial media and decreased proportion of full muscularized vessels.Alleviation of right ventricular hypertrophy was indicated by declined Fulton index,the cross-sectional area of right ventricular cardiomyocytes as well as collagen deposition.Effective recovery of right ventricular function was evidenced by increased pulmonary artery flow acceleration time/pulmonary artery flow ejection time ratio.These findings underscore the potential of restoring BMPR2 signaling through pulmonary endothelial cell-specific LNPs for treating PAH.
